Literature DB >> 33106857

Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations.

Olivera Casar-Borota1,2, Henning Bünsow Boldt3,4, Britt Edén Engström5,6, Marianne Skovsager Andersen7,8, Bertrand Baussart9, Daniel Bengtsson10,11, Katarina Berinder12,13, Bertil Ekman14,15, Ulla Feldt-Rasmussen16,17, Charlotte Höybye12,13, Jens Otto L Jørgensen18, Anders Jensen Kolnes19,20, Márta Korbonits21,22, Åse Krogh Rasmussen23, John R Lindsay24,25, Paul Benjamin Loughrey25,26, Dominique Maiter27, Emilija Manojlovic-Gacic28, Jens Pahnke29,30,31, Pietro Luigi Poliani32, Vera Popovic33, Oskar Ragnarsson34,35, Camilla Schalin-Jäntti36, David Scheie37, Miklós Tóth38, Chiara Villa39,40,41, Martin Wirenfeldt3,4, Jacek Kunicki42, Pia Burman43.   

Abstract

CONTEXT: Aggressive pituitary tumors (APTs) are characterized by unusually rapid growth and lack of response to standard treatment. About 1% to 2% develop metastases being classified as pituitary carcinomas (PCs). For unknown reasons, the corticotroph tumors are overrepresented among APTs and PCs. Mutations in the alpha thalassemia/mental retardation syndrome X-linked (ATRX) gene, regulating chromatin remodeling and telomere maintenance, have been implicated in the development of several cancer types, including neuroendocrine tumors.
OBJECTIVE: To study ATRX protein expression and mutational status of the ATRX gene in APTs and PCs.
DESIGN: We investigated ATRX protein expression by using immunohistochemistry in 30 APTs and 18 PCs, mostly of Pit-1 and T-Pit cell lineage. In tumors lacking ATRX immunolabeling, mutational status of the ATRX gene was explored.
RESULTS: Nine of the 48 tumors (19%) demonstrated lack of ATRX immunolabelling with a higher proportion in patients with PCs (5/18; 28%) than in those with APTs (4/30;13%). Lack of ATRX was most common in the corticotroph tumors, 7/22 (32%), versus tumors of the Pit-1 lineage, 2/24 (8%). Loss-of-function ATRX mutations were found in all 9 ATRX immunonegative cases: nonsense mutations (n = 4), frameshift deletions (n = 4), and large deletions affecting 22-28 of the 36 exons (n = 3). More than 1 ATRX gene defect was identified in 2 PCs.
CONCLUSION: ATRX mutations occur in a subset of APTs and are more common in corticotroph tumors. The findings provide a rationale for performing ATRX immunohistochemistry to identify patients at risk of developing aggressive and potentially metastatic pituitary tumors.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society.

Entities:  

Keywords:  ATRX (alpha thalassemia/mental retardation syndrome X-linked); Cushing’s disease; aggressive PitNETs; pituitary adenoma; pituitary carcinoma

Mesh:

Substances:

Year:  2021        PMID: 33106857      PMCID: PMC7993578          DOI: 10.1210/clinem/dgaa749

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  43 in total

1.  Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma-Tailored Gene Panel.

Authors:  Angela Zacher; Kerstin Kaulich; Stefanie Stepanow; Marietta Wolter; Karl Köhrer; Jörg Felsberg; Bastian Malzkorn; Guido Reifenberger
Journal:  Brain Pathol       Date:  2016-04-19       Impact factor: 6.508

2.  Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes.

Authors:  Jan J Molenaar; Jan Koster; Danny A Zwijnenburg; Peter van Sluis; Linda J Valentijn; Ida van der Ploeg; Mohamed Hamdi; Johan van Nes; Bart A Westerman; Jennemiek van Arkel; Marli E Ebus; Franciska Haneveld; Arjan Lakeman; Linda Schild; Piet Molenaar; Peter Stroeken; Max M van Noesel; Ingrid Ora; Evan E Santo; Huib N Caron; Ellen M Westerhout; Rogier Versteeg
Journal:  Nature       Date:  2012-02-22       Impact factor: 49.962

3.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.

Authors:  Donavan T Cheng; Talia N Mitchell; Ahmet Zehir; Ronak H Shah; Ryma Benayed; Aijazuddin Syed; Raghu Chandramohan; Zhen Yu Liu; Helen H Won; Sasinya N Scott; A Rose Brannon; Catherine O'Reilly; Justyna Sadowska; Jacklyn Casanova; Angela Yannes; Jaclyn F Hechtman; Jinjuan Yao; Wei Song; Dara S Ross; Alifya Oultache; Snjezana Dogan; Laetitia Borsu; Meera Hameed; Khedoudja Nafa; Maria E Arcila; Marc Ladanyi; Michael F Berger
Journal:  J Mol Diagn       Date:  2015-03-20       Impact factor: 5.568

4.  The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011.

Authors:  Axel Tjörnstrand; Kerstin Gunnarsson; Max Evert; Erik Holmberg; Oskar Ragnarsson; Thord Rosén; Helena Filipsson Nyström
Journal:  Eur J Endocrinol       Date:  2014-08-01       Impact factor: 6.664

5.  A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up.

Authors:  Jacqueline Trouillas; Pascal Roy; Nathalie Sturm; Emmanuelle Dantony; Christine Cortet-Rudelli; Gabriel Viennet; Jean-François Bonneville; Richard Assaker; Carole Auger; Thierry Brue; Aurélie Cornelius; Henry Dufour; Emmanuel Jouanneau; Patrick François; Françoise Galland; François Mougel; François Chapuis; Laurent Villeneuve; Claude-Alain Maurage; Dominique Figarella-Branger; Gérald Raverot; A Barlier; M Bernier; F Bonnet; F Borson-Chazot; G Brassier; S Caulet-Maugendre; O Chabre; P Chanson; J F Cottier; B Delemer; E Delgrange; L Di Tommaso; S Eimer; S Gaillard; M Jan; J J Girard; V Lapras; H Loiseau; J G Passagia; M Patey; A Penfornis; J Y Poirier; G Perrin; A Tabarin
Journal:  Acta Neuropathol       Date:  2013-02-12       Impact factor: 17.088

6.  Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma.

Authors:  Sylvie Job; Irena Draskovic; Nelly Burnichon; Alexandre Buffet; Jérôme Cros; Charles Lépine; Annabelle Venisse; Estelle Robidel; Virginie Verkarre; Tchao Meatchi; Mathilde Sibony; Laurence Amar; Jérôme Bertherat; Aurélien de Reyniès; Arturo Londoño-Vallejo; Judith Favier; Luis Jaime Castro-Vega; Anne-Paule Gimenez-Roqueplo
Journal:  Clin Cancer Res       Date:  2018-10-09       Impact factor: 12.531

7.  Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX.

Authors:  David Clynes; Clare Jelinska; Barbara Xella; Helena Ayyub; Caroline Scott; Matthew Mitson; Stephen Taylor; Douglas R Higgs; Richard J Gibbons
Journal:  Nat Commun       Date:  2015-07-06       Impact factor: 14.919

8.  Driver mutations in USP8 wild-type Cushing's disease.

Authors:  Silviu Sbiera; Luis Gustavo Perez-Rivas; Lyudmyla Taranets; Isabel Weigand; Jörg Flitsch; Elisabeth Graf; Camelia-Maria Monoranu; Wolfgang Saeger; Christian Hagel; Jürgen Honegger; Guillaume Assie; Ad R Hermus; Günter K Stalla; Sabine Herterich; Cristina L Ronchi; Timo Deutschbein; Martin Reincke; Tim M Strom; Nikita Popov; Marily Theodoropoulou; Martin Fassnacht
Journal:  Neuro Oncol       Date:  2019-10-09       Impact factor: 12.300

9.  MYCN amplification and ATRX mutations are incompatible in neuroblastoma.

Authors:  Maged Zeineldin; Sara Federico; Xiang Chen; Yiping Fan; Beisi Xu; Elizabeth Stewart; Xin Zhou; Jongrye Jeon; Lyra Griffiths; Rosa Nguyen; Jackie Norrie; John Easton; Heather Mulder; Donald Yergeau; Yanling Liu; Jianrong Wu; Collin Van Ryn; Arlene Naranjo; Michael D Hogarty; Marcin M Kamiński; Marc Valentine; Shondra M Pruett-Miller; Alberto Pappo; Jinghui Zhang; Michael R Clay; Armita Bahrami; Peter Vogel; Seungjae Lee; Anang Shelat; Jay F Sarthy; Michael P Meers; Rani E George; Elaine R Mardis; Richard K Wilson; Steven Henikoff; James R Downing; Michael A Dyer
Journal:  Nat Commun       Date:  2020-02-14       Impact factor: 14.919

10.  Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations.

Authors:  Olivera Casar-Borota; Henning Bünsow Boldt; Britt Edén Engström; Marianne Skovsager Andersen; Bertrand Baussart; Daniel Bengtsson; Katarina Berinder; Bertil Ekman; Ulla Feldt-Rasmussen; Charlotte Höybye; Jens Otto L Jørgensen; Anders Jensen Kolnes; Márta Korbonits; Åse Krogh Rasmussen; John R Lindsay; Paul Benjamin Loughrey; Dominique Maiter; Emilija Manojlovic-Gacic; Jens Pahnke; Pietro Luigi Poliani; Vera Popovic; Oskar Ragnarsson; Camilla Schalin-Jäntti; David Scheie; Miklós Tóth; Chiara Villa; Martin Wirenfeldt; Jacek Kunicki; Pia Burman
Journal:  J Clin Endocrinol Metab       Date:  2021-03-25       Impact factor: 5.958

View more
  10 in total

1.  Alternative Lengthening of Telomeres (ALT) and Telomerase Reverse Transcriptase Promoter Methylation in Recurrent Adult and Primary Pediatric Pituitary Neuroendocrine Tumors.

Authors:  Hiba Alzoubi; Simone Minasi; Francesca Gianno; Manila Antonelli; Francesca Belardinilli; Felice Giangaspero; Marie-Lise Jaffrain-Rea; Francesca Romana Buttarelli
Journal:  Endocr Pathol       Date:  2022-01-06       Impact factor: 3.943

Review 2.  Aggressive pituitary tumours and pituitary carcinomas.

Authors:  Gérald Raverot; Mirela Diana Ilie; Hélène Lasolle; Vincent Amodru; Jacqueline Trouillas; Frédéric Castinetti; Thierry Brue
Journal:  Nat Rev Endocrinol       Date:  2021-09-07       Impact factor: 43.330

Review 3.  Genetics of Cushing's disease: from the lab to clinical practice.

Authors:  Marily Theodoropoulou; Martin Reincke
Journal:  Pituitary       Date:  2022-07-19       Impact factor: 3.599

Review 4.  Genetic Basis of ACTH-Secreting Adenomas.

Authors:  Pietro Locantore; Rosa Maria Paragliola; Gianluca Cera; Roberto Novizio; Ettore Maggio; Vittoria Ramunno; Andrea Corsello; Salvatore Maria Corsello
Journal:  Int J Mol Sci       Date:  2022-06-19       Impact factor: 6.208

5.  Case Report: Malignant Primary Sellar Paraganglioma With Unusual Genetic and Imaging Features.

Authors:  Stefan Stojanoski; Henning Bünsow Boldt; Dusko Kozic; Attila Patócs; Márta Korbonits; Milica Medic-Stojanoska; Olivera Casar-Borota
Journal:  Front Oncol       Date:  2021-11-23       Impact factor: 6.244

6.  TP53 mutations in functional corticotroph tumors are linked to invasion and worse clinical outcome.

Authors:  Luis Gustavo Perez-Rivas; Julia Simon; Adriana Albani; Sicheng Tang; Sigrun Roeber; Guillaume Assié; Timo Deutschbein; Martin Fassnacht; Monica R Gadelha; Ad R Hermus; Günter K Stalla; Maria A Tichomirowa; Roman Rotermund; Jörg Flitsch; Michael Buchfelder; Isabella Nasi-Kordhishti; Jürgen Honegger; Jun Thorsteinsdottir; Wolfgang Saeger; Jochen Herms; Martin Reincke; Marily Theodoropoulou
Journal:  Acta Neuropathol Commun       Date:  2022-09-19       Impact factor: 7.578

Review 7.  Aggressive corticotroph tumors and carcinomas.

Authors:  Hélène Lasolle; Alexandre Vasiljevic; Emmanuel Jouanneau; Mirela Diana Ilie; Gérald Raverot
Journal:  J Neuroendocrinol       Date:  2022-08-18       Impact factor: 3.870

8.  Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients.

Authors:  Pia Burman; Jacqueline Trouillas; Marco Losa; Ann McCormack; Stephan Petersenn; Vera Popovic; Marily Theodoropoulou; Gerald Raverot; Olaf M Dekkers
Journal:  Eur J Endocrinol       Date:  2022-09-19       Impact factor: 6.558

Review 9.  Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.

Authors:  Masaaki Yamamoto; Takahiro Nakao; Wataru Ogawa; Hidenori Fukuoka
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-16       Impact factor: 5.555

10.  Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations.

Authors:  Olivera Casar-Borota; Henning Bünsow Boldt; Britt Edén Engström; Marianne Skovsager Andersen; Bertrand Baussart; Daniel Bengtsson; Katarina Berinder; Bertil Ekman; Ulla Feldt-Rasmussen; Charlotte Höybye; Jens Otto L Jørgensen; Anders Jensen Kolnes; Márta Korbonits; Åse Krogh Rasmussen; John R Lindsay; Paul Benjamin Loughrey; Dominique Maiter; Emilija Manojlovic-Gacic; Jens Pahnke; Pietro Luigi Poliani; Vera Popovic; Oskar Ragnarsson; Camilla Schalin-Jäntti; David Scheie; Miklós Tóth; Chiara Villa; Martin Wirenfeldt; Jacek Kunicki; Pia Burman
Journal:  J Clin Endocrinol Metab       Date:  2021-03-25       Impact factor: 5.958

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.